Opens in a new tab

Sanofi v Accord Healthcare (CFI, 8 May 2025)

Date8 May 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionGeneric Order
Registry referenceORD_10064/2025
PartiesSanofi B.V., Sanofi A/S, Sanofi Belgium, Sanofi-Aventis GmbH, Sanofi - Produtos Farmaceuticos Lda, Sanofi-Aventis Deutschland GmbH, Sanofi …

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 8 May 2025, the judge rapporteur of the Munich Local Division, dealing with Sanofi’s four joined actions against Accord, STADA, Reddy and Zentiva under EP 2 493 466 (UPC_CFI_145/2024 to UPC_CFI_148/2024, with the counterclaims for revocation), deferred the preliminary objections to the main proceedings and referred the remaining pending requests to the panel for decision after the oral hearing, and set the timetable. His observations on Rule 263 and on poorly drafted requests are of practical interest.

Question

Should the preliminary objections, repeatedly amended requests and requests for information be decided at the interim stage?

Decision

Using his powers under Rule 332, the judge rapporteur preferred to await the decision of the EPO Board of Appeal (hearing on 2 to 4 June 2025), the French designation having been invalidated at first instance in France. As Sanofi had still not, despite several invitations, filed unambiguous requests, no further opportunity to cure will be given: the panel will interpret the claims, which alone bind it (Art. 76(1) UPCA), and the extra cost caused may weigh in the costs decision (Art. 69(3) UPCA). Adding auxiliary requests for indirect infringement and a request for an interim award of damages does not appear to fall under Rule 263, since the patent and product remain the same. An order to produce sales figures would be premature. The rejoinder is due within two months, the written procedure closes on 8 August 2025 and the oral hearing remains set for 14 to 17 October 2025.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 34, 47, 69(3) and 76(1)
Rules of Procedure
Rules 9, 13, 20.2, 29, 118, 119, 125, 263, 265, 332 and 333
Case law cited
Court of Appeal, UPC_CoA_456/2024 and UPC_CoA_169/2025, Munich Local Division, 22 September 2024 (UPC_CFI_114/2024)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic Order
Outcome (Dhenne Avocats summary)
Le juge rapporteur renvoie les exceptions préliminaires au fond et les demandes pendantes à la formation après l'audience, refuse toute nouvelle régularisation des demandes de Sanofi et fixe le calendrier jusqu'à l'audience d'octobre 2025.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 493 466
Novel antitumoral use of cabazitaxel
recorded proprietor: Sanofi SA
Mentioned in the analysis (role not qualified)
Also mentioned in 12 other decision(s): Sanofi v Reddy Pharma (CFI, 12 December 2025) · Zentiva France v Sanofi Mature IP (CFI, 24 January 2025) · Accord Healthcare v Sanofi (Paris Judicial Court, RG 21/06416, 2024) · Sanofi v Accord Healthcare (CFI, ORD_69482/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, ORD_69480/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, 17 July 2025) · Sanofi v Zentiva France (CFI, 27 June 2025) · Medac v Sanofi Mature IP (CFI, 19 March 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.